Specificity/NN
of/IN
Intracellular/JJ
Trans-S/NNS
plicing/VBG
Reaction/NN
by/IN
hTE/NN
RT-Targeting/NN
G/NN
roup/NN
11/CD
ntron/NN
./.
====================
Recent/JJ
anti-cancer/JJ
approaches/NNS
have/VBP
been/VBN
based/VBN
to/TO
target/NN
tumor-specifically/RB
associated/VBN
and/or/CC
causative/JJ
====================
molecules/NNS
such/JJ
as/IN
RNAs/NNS
or/CC
proteins/NNS
./.
====================
As/IN
this/DT
specifically/RB
targeted/VBN
anti-cancer/JJ
modulator/NN
,/,
we/PRP
have/VBP
previously/RB
described/VBN
a/DT
novel/JJ
human/JJ
cancer/NN
gene/NN
therapeutic/JJ
agent/NN
that/WDT
is/VBZ
Tetrahymena/JJ
group/NN
I/NN
intron-based/VBD
frans-splicing/VBG
ribozyme/NN
which/WDT
can/MD
reprogram/VB
and/CC
replace/NN
human/JJ
telomerase/NN
reverse/JJ
transcriptase/NN
(/(
hTERT/NN
)/)
RNA/NN
to/TO
selectively/RB
induce/VBP
tumor-specific/JJ
cytotoxicity/NN
in/IN
cancer/NN
cells/NNS
expressing/VBG
the/DT
target/NN
RNA/NN
./.
====================
Moreover/RB
,/,
the/DT
specific/JJ
ribozyme/NN
has/VBZ
been/VBN
shown/VBN
to/TO
efficiently/RB
retard/JJ
tumor/NN
tissues/NNS
in/IN
xenograft/NN
mice/NNS
which/WDT
had/VBD
been/VBN
inoculated/VBN
with/IN
hTERT-expressing/JJ
human/JJ
cancer/NN
cells/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
assessed/VBD
specificity/NN
of/IN
frans-splicing/VBG
reaction/NN
in/IN
cells/NNS
to/TO
evaluate/VB
the/DT
therapeutic/JJ
feasibility/NN
of/IN
the/DT
specific/JJ
ribozyme/NN
./.
====================
In/IN
order/NN
to/TO
analyze/VB
the/DT
frans-spliced/JJ
products/NNS
by/IN
the/DT
specific/JJ
ribozyme/NN
in/IN
hTERT-positive/JJ
cells/NNS
,/,
RT/NN
,/,
5'-end/NN
RACE-PCR/NN
,/,
and/CC
sequencing/NN
reactions/NNS
of/IN
the/DT
spliced/VBN
RNAs/NNS
were/VBD
employed/VBN
./.
====================
Then/RB
,/,
whole/JJ
analyzed/VBD
products/NNS
resulted/VBD
from/IN
reactions/NNS
only/RB
with/IN
the/DT
hTERT/NN
RNA/NN
./.
====================
This/DT
study/NN
suggested/VBD
that/IN
the/DT
developed/VBN
ribozyme/NN
perform/NN
highly/RB
specific/JJ
RNA/NN
replacement/NN
of/IN
the/DT
target/NN
RNA/NN
in/IN
cells/NNS
,/,
hence/RB
frans-splicing/VBG
ribozyme/NN
will/MD
be/VB
one/CD
of/IN
specific/JJ
agents/NNS
for/IN
genetic/JJ
approach/NN
to/TO
revert/VB
cancer/NN
./.
====================
One/CD
of/IN
major/JJ
concerns/NNS
for/IN
cancer/NN
gene/NN
therapy/NN
is/VBZ
development/NN
of/IN
genetic/JJ
approach/NN
to/TO
specific/JJ
cancer/NN
cell/NN
retardation/NN
./.
====================
Especially/RB
,/,
specific/JJ
messages/NNS
associated/VBN
with/IN
and/or/CC
causative/JJ
to/TO
a/DT
broad/JJ
range/NN
of/IN
human/JJ
cancers/NNS
are/VBP
now/RB
being/VBG
intensively/RB
identified/VBN
(/(
Strausberg/NN
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
Based/VBN
on/IN
these/DT
specific/JJ
messages/NNS
,/,
large/JJ
efforts/NNS
====================
to/TO
modulate/VB
cancers/NNS
have/VBP
been/VBN
based/VBN
on/IN
specific/JJ
knock/NN
down/RB
the/DT
messages/NNS
using/VBG
inhibitory/JJ
RNAs/NNS
such/JJ
as/IN
siRNA/JJ
or/CC
ribozyme/NN
,/,
or/CC
transcriptional/JJ
targeting/VBG
using/VBG
the/DT
cancer-specific/JJ
promoters/enhancers/NNS
(/(
McCormick/NNP
eta/NN
!/CD
./.
,/,
2001/CD
)/)
./.
====================
However/RB
,/,
difficulties/VBZ
to/TO
specifically/RB
or/CC
completely/RB
down-regulate/VB
the/DT
oncogenic/JJ
transcripts/NNS
and/CC
leaky/VBP
promoter/enhancer/NN
activity/NN
in/IN
normal/JJ
tissues/NNS
could/MD
restrain/VB
their/PRP$
usefulness/NN
./.
====================
Thus/RB
,/,
more/RBR
specific/JJ
and/CC
effective/JJ
anti-cancer/JJ
approach/NN
will/MD
be/VB
warranted/VBN
./.
====================
Tetrahymena/DT
group/NN
I/NN
intron/NN
ribozymes/NNS
have/VBP
been/VBN
shown/VBN
to/TO
revise/VB
mutant/JJ
RNAs/NNS
which/WDT
are/VBP
involved/VBN
in/IN
human/JJ
genetic/JJ
or/CC
malignant/JJ
diseases/NNS
by/IN
frans-splicing/VBG
with/IN
the/DT
target/NN
transcripts/NNS
,/,
and/CC
moreover/RB
,/,
reprogram/RB
and/CC
replace/RB
specific/JJ
viral/JJ
transcripts/NNS
also/RB
by/IN
frans-splicing/VBG
to/TO
selectively/RB
stimulate/VBP
a/DT
new/JJ
gene/NN
activity/NN
in/IN
the/DT
viral/JJ
RNA-expressing/JJ
cells/NNS
(/(
Lan/JJ
eta/NN
!/NNP
./.
,/,
1998/CD
;/:
Phylactou/NNP
eta/NN
!/NNP
./.
,/,
1998/CD
;/:
Rogers/NNS
etal./FW
,/,
2002/CD
;/:
Ryu/NNP
et/FW
al./FW
,/,
2003/CD
;/:
Shin/NN
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
Furthermore/RB
,/,
we/PRP
have/VBP
recently/RB
developed/VBN
specific/JJ
frans-splicing/VBG
ribozymes/NNS
which/WDT
can/MD
reprogram/VB
cancerÂ­/MD
specific/JJ
human/JJ
telomerase/NN
reverse/JJ
transcriptase/NN
(/(
hTERT/NN
)/)
RNA/NN
to/TO
selectively/RB
induce/VBP
cytotoxin/NN
gene/NN
activity/NN
in/IN
cancer/NN
cells/NNS
expressing/VBG
the/DT
target/NN
RNA/NN
,/,
and/CC
thereby/RB
selectively/RB
retarding/VBG
the/DT
growth/NN
of/IN
those/DT
cancer/NN
cells/NNS
(/(
Jung/NN
et/FW
al./FW
,/,
2005/CD
;/:
Kwon/NNP
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
Importantly/RB
,/,
this/DT
====================
specific/JJ
ribozyme-mediated/JJ
selective/JJ
regression/NN
of/IN
tumors/NNS
was/VBD
observed/VBN
in/IN
mice/NNS
which/WDT
had/VBD
been/VBN
inoculated/VBN
subcutaneously/RB
with/IN
hTERT-positive/JJ
cancer/NN
cells/NNS
(/(
Kwon/NN
etal./FW
,/,
2005/CD
)/)
./.
====================
Thus/RB
,/,
the/DT
hTERT/NN
RNA-targeting/JJ
trans-splicing/VBG
ribozyme/NN
will/MD
be/VB
a/DT
novel/JJ
agent/NN
to/TO
specifically/RB
deliver/RB
anti-cancer/JJ
genes/NNS
into/IN
cancer/NN
cells/NNS
by/IN
selectively/RB
targeting/VBG
and/CC
replacing/VBG
cancer-specific/JJ
messages/NNS
./.
====================
Of/IN
note/NN
,/,
the/DT
trans-splicing/VBG
ribozyme/NN
will/MD
have/VBP
the/DT
advantage/NN
of/IN
cumulative/JJ
effects/NNS
of/IN
reduction/NN
of/IN
target/NN
RNA/NN
level/NN
and/CC
simultaneous/JJ
induction/NN
of/IN
anti-cancer/JJ
gene/NN
activity/NN
in/IN
the/DT
target/NN
RNA-expressing/JJ
cancer/NN
cells/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
analyzed/VBD
specific/JJ
activity/NN
of/IN
the/DT
trans-splicing/VBG
reaction/NN
in/IN
cells/NNS
expressing/VBG
the/DT
target/NN
RNA/NN
by/IN
the/DT
hTERT-targeting/JJ
specific/JJ
ribozyme/NN
that/DT
has/VBZ
been/VBN
observed/VBN
to/TO
induce/VB
in/IN
vivo/FW
tumor/NN
regression/NN
./.
====================
A/DT
specific/JJ
group/NN
I/NN
ribozyme/NN
that/DT
recognizes/VBZ
uridine/NN
at/IN
position/NN
21/CD
(/(
U21/NN
)/)
of/IN
hTERT/NN
RNA/NN
was/VBD
constructed/VBN
because/IN
U21/NN
on/IN
the/DT
hTERT/NN
RNA/NN
was/VBD
the/DT
most/JJS
accessible/JJ
to/TO
the/DT
ribozyme/NN
from/IN
an/DT
RNA/NN
mapping/VBG
====================
strategy/NN
,/,
and/CC
moreover/RB
,/,
the/DT
frans-sphcing/NN
efficiency/NN
at/IN
U21/NN
was/VBD
superior/JJ
to/TO
any/DT
other/JJ
sites/NNS
in/IN
the/DT
target/NN
RNA/NN
(/(
Kwon/NN
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
Internal/JJ
guide/NN
sequence/NN
(/(
IGS/NN
,/,
5'-GGCAGG-3/NN
'/``
)/)
of/IN
the/DT
ribozyme/NN
was/VBD
modified/VBN
to/TO
harbor/VB
an/DT
extension/NN
of/IN
P1/NN
helix/NN
and/CC
an/DT
addition/NN
of/IN
6/CD
nt/NNS
P10/NN
helix/NN
combined/JJ
with/IN
a/DT
325-nt-long/JJ
antisense/JJ
sequence/NN
against/IN
the/DT
downstream/JJ
region/NN
(/(
+30/CD
to/TO
+354/CD
residue/NN
)/)
of/IN
U21/NN
of/IN
the/DT
hTERT/NN
RNA/NN
for/IN
the/DT
functional/JJ
expression/NN
in/IN
mammalian/JJ
cells/NNS
as/IN
described/VBN
(/(
Kwon/NNP
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
In/IN
addition/NN
,/,
firefly/RB
luciferase/NN
RNA/NN
was/VBD
inserted/VBN
as/IN
3/CD
'/``
exon/NN
of/IN
the/DT
modified/VBN
ribozyme/NN
,/,
designated/VBN
Rib21AS-Fluc/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
SV40/NN
promoter-based/VBN
expression/NN
vector/NN
was/VBD
constructed/VBN
to/TO
express/VB
the/DT
ribozyme/NN
in/IN
cells/NNS
./.
====================
This/DT
specific/JJ
hTERT-targeting/VBG
ribozyme/NN
was/VBD
shown/VBN
to/TO
accurately/RB
replace/VBP
hTERT/NN
RNA/NN
with/IN
the/DT
intended/JJ
sequence/NN
attached/VBD
to/TO
the/DT
3/CD
1/CD
end/NN
of/IN
the/DT
ribozyme/NN
in/IN
cells/NNS
as/IN
well/RB
as/IN
in/IN
test/NN
tube/NN
./.
====================
In/IN
addition/NN
,/,
the/DT
ribozyme/NN
can/MD
inhibit/VB
telomerase/NN
function/NN
in/IN
the/DT
cells/NNS
by/IN
reducing/VBG
the/DT
amount/NN
of/IN
the/DT
targeted/VBN
RNA/NN
./.
====================
Moreover/RB
,/,
the/DT
ribozyme/NN
can/MD
selectively/RB
induce/VBP
cytotoxin/NN
gene/NN
activity/NN
or/CC
suicide/JJ
gene/NN
activity/NN
in/IN
the/DT
hTERT/NN
RNA-expressing/JJ
cancer/NN
cells/NNS
,/,
and/CC
thereby/RB
specifically/RB
and/CC
effectively/RB
impeded/VBD
the/DT
growth/NN
of/IN
these/DT
cells/NNS
in/IN
xenograft/NN
mice/NNS
which/WDT
had/VBD
been/VBN
inoculated/VBN
with/IN
the/DT
human/JJ
hTERT-positive/JJ
cancer/NN
cells/NNS
as/IN
well/RB
as/IN
in/IN
vitro/FW
cell/NN
culture/NN
(/(
Kwon/NN
etal./FW
,/,
2005/CD
)/)
====================
RNA/NN
tagging/VBG
approach/NN
was/VBD
employed/VBN
to/TO
analyze/VB
the/DT
intracellular/JJ
specificity/NN
of/IN
the/DT
ribozyme/NN
,/,
Rib21/NN
AS-Fluc/JJ
,/,
at/IN
molecular/JJ
level/NN
./.
====================
To/TO
this/DT
end/NN
,/,
we/PRP
determined/VBD
whether/IN
the/DT
ribozyme/NN
was/VBD
reacting/VBG
with/IN
RNAs/NNS
other/JJ
than/IN
the/DT
targeted/VBN
====================
hTERT/NN
RNAs/NNS
inside/NN
ribozyme-transfected/JJ
cells/NNS
by/IN
performing/VBG
RT/NN
and/CC
5'-end/NN
RACE/NN
(/(
rapid/JJ
amplification/NN
of/IN
====================
cDNA/NN
ends/NNS
)/)
PCR/NN
reaction/NN
of/IN
frans-spliced/JJ
products/NNS
in/IN
the/DT
hTERT-/NN
expressing/VBG
cells/NNS
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
293/CD
cells/NNS
were/VBD
used/VBN
for/IN
ribozyme/NN
transfection/NN
./.
====================
The/DT
cells/NNS
were/VBD
transfected/VBN
with/IN
1/CD
ug/NN
ribozyme/NN
expression/NN
vector/NN
using/VBG
4ul/JJ
Lipofectamine/NN
(/(
Invitrogen/NN
)/)
./.
====================
Twenty/CD
four/CD
h/NN
after/IN
transfection/NN
,/,
total/JJ
RNA/NN
was/VBD
isolated/VBN
and/CC
reverse/JJ
transcribed/VBN
with/IN
random/JJ
primer/NN
./.
====================
The/DT
3/CD
'/``
ends/NNS
of/IN
cDNA/NN
products/NNS
were/VBD
tailed/VBN
with/IN
====================
dATP/NN
using/VBG
terminal/JJ
transferase/NN
(/(
Roche/NNP
)/)
,/,
and/CC
adaptor/NN
oligonucleotides/NNS
(/(
TAKARA/NN
)/)
were/VBD
added/VBN
to/TO
the/DT
end/NN
./.
====================
The/DT
cDNAs/NNS
were/VBD
then/RB
amplified/VBD
using/VBG
10/CD
pmol/NN
adaptor/NN
5/CD
'/``
primer/NN
(/(
Takara/NN
)/)
and/CC
luciferase/NN
3/CD
1/CD
primer/NN
(/(
5'-GCGCAACTG/NN
CAACTCCGATAA/NN
)/)
./.
====================
We/PRP
cloned/VBD
the/DT
amplified/VBN
cDNAs/NNS
,/,
and/CC
twenty/JJ
nine/CD
different/JJ
clones/NNS
were/VBD
sequenced/VBN
./.
====================
Then/RB
,/,
the/DT
sequence/NN
of/IN
the/DT
cDNAs/NNS
revealed/VBD
that/IN
whole/JJ
analyzed/VBD
products/NNS
resulted/VBD
from/IN
frans-splicing/VBG
reactions/NNS
only/RB
with/IN
the/DT
targeted/VBN
hTERT/NN
RNA/NN
,/,
not/RB
with/IN
any/DT
other/JJ
RNAs/NNS
,/,
which/WDT
strongly/RB
implied/VBN
that/DT
the/DT
ribozyme/NN
reacted/VBD
with/IN
and/CC
replaced/VBD
only/RB
targeted/VBN
cellular/JJ
transcripts/NNS
,/,
hTERT/NN
RNA/NN
,/,
with/IN
its/PRP$
3/CD
'/``
exon/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Although/IN
assessment/NN
of/IN
more/RBR
frans-spliced/JJ
products/NNS
might/MD
be/VB
necessary/JJ
,/,
this/DT
result/NN
suggests/VBZ
that/IN
the/DT
group/NN
I/NN
intron-based/VBD
ribozyme/NN
exert/VBP
highly/RB
target/NN
RNA-specific/JJ
frans-splicing/VBG
activity/NN
in/IN
cellular/JJ
milieu/NN
./.
====================
Therefore/RB
,/,
our/PRP$
ribozyme/NN
construct/NN
had/VBD
minimized/VBN
the/DT
degree/NN
to/TO
which/WDT
target/NN
RNA-negative/JJ
normal/JJ
cells/NNS
could/MD
be/VB
harmed/VBN
due/JJ
to/TO
nonspecific/JJ
transgene/NN
induction/NN
via/IN
nonspecific/JJ
targeting/VBG
and/CC
RNA/NN
replacement/NN
./.
====================
This/DT
study/NN
suggests/VBZ
that/IN
group/NN
l-based/VBD
frans-splicing/VBG
ribozymes/NNS
could/MD
be/VB
specific/JJ
anti-cancer/JJ
agents/NNS
to/TO
stimulate/VB
transgene/NN
activity/NN
very/RB
specifically/RB
via/IN
cancer-specific/JJ
RNA/NN
replacement/NN
./.
====================
Together/RB
with/IN
the/DT
development/NN
of/IN
an/DT
efficient/JJ
gene/NN
transfer/NN
system/NN
,/,
cancer/NN
specific/JJ
RNA-targeted/JJ
gene/NN
delivery/NN
strategy/NN
based/VBN
on/IN
RNA/NN
replacement/NN
will/MD
be/VB
of/IN
specific/JJ
and/CC
effective/JJ
utility/NN
for/IN
the/DT
modulation/NN
of/IN
human/JJ
cancers/NNS
./.
====================
